CBIO (Crescent Biopharma, Inc.) Stock Financials & Earnings | Market Cap Arena

CBIO (Crescent Biopharma, Inc.) Stock Financials & Earnings | Market Cap Arena

CBIOCrescent Biopharma, Inc.

Mkt Cap$345M

Healthcare·Biotechnology·🇺🇸 United States·NASDAQ

Revenue (TTM)$41M

Net Income (TTM)-$141M

EPS (TTM)-$4.87

Free Cash Flow (TTM)-$23M

Gross Margin95.9%

Op. Margin-368.6%

Net Margin-340.8%

FCF Margin-56.5%

P/S Ratio (TTM)8.3x

P/E Ratio (TTM)—

YoY Rev Growth—

Employees—

Earnings Reports

Revenue & Profitability

Quarter	Revenue	Gross Profit	Op. Income
Q1 23	$0	-$263K	-$11M
Q2 23	$0	-$266K	-$9M
Q3 23	$0	-$270K	-$10M
Q4 23	$10K	$10K	-$10M
Q1 24	$0	-$15K	-$11M
Q2 24	$0	-$12K	-$10M
Q3 24	$0	-$8K	-$11M
Q4 24	$0	$27K	-$36M
Q1 25	$0	$0	-$2M
Q2 25	$0	-$2K	-$21M
Q3 25	$31M	$29M	-$26M
Q4 25	$11M	$11M	-$103M

Valuation

Quarter	P/S	P/E
Q1 23	—	—
Q2 23	—	—
Q3 23	—	—
Q4 23	34528.6x	—
Q1 24	34528.6x	—
Q2 24	34528.6x	—
Q3 24	34528.6x	—
Q4 24	—	—
Q1 25	—	—
Q2 25	—	—
Q3 25	11.3x	—
Q4 25	8.3x	—

Operating Cash Flow

Quarter	Operating CF	Free CF
Q1 23	-$12M	-$12M
Q2 23	-$7M	-$7M
Q3 23	-$9M	-$9M
Q4 23	-$8M	-$8M
Q1 24	-$11M	-$11M
Q2 24	-$9M	-$9M
Q3 24	$19M	$19M
Q4 24	-$4M	-$4M
Q1 25	-$5M	-$5M
Q2 25	-$22M	-$22M
Q3 25	-$18M	-$18M
Q4 25	$22M	$22M

Capital Expenditures

CapEx

Quarter	CapEx
Q1 23	$2K
Q2 23	$11K
Q3 23	$8K
Q4 23	$803
Q1 24	$7K
Q2 24	$3K
Q3 24	$10K
Q4 24	$0
Q1 25	$0
Q2 25	$140K
Q3 25	$586K
Q4 25	$82K

OpEx vs Revenue Growth (YoY)

Quarter	Revenue Growth	OpEx Growth
Q1 23	—	-25.4%
Q2 23	-100.0%	-33.5%
Q3 23	—	+11.9%
Q4 23	+113.3%	-9.0%
Q1 24	—	+1.6%
Q2 24	—	+16.0%
Q3 24	—	+14.5%
Q4 24	-100.0%	+275.6%
Q1 25	—	-78.4%
Q2 25	—	+103.0%
Q3 25	—	+402.5%
Q4 25	—	+216.6%

Stock-Based Compensation

Quarter	SBC ($)	% of Revenue
Q1 23	$870K	—
Q2 23	$0	—
Q3 23	$0	—
Q4 23	$0	0.0%
Q1 24	$1M	—
Q2 24	$1M	—
Q3 24	$0	—
Q4 24	$1M	—
Q1 25	$405K	—
Q2 25	$0	—
Q3 25	$0	0.0%
Q4 25	$7M	67.4%

OpEx Breakdown

Quarter	R&D	G&A
Q1 23	$5M	$6M
Q2 23	$4M	$5M
Q3 23	$5M	$5M
Q4 23	$5M	$4M
Q1 24	$6M	$5M
Q2 24	$6M	$4M
Q3 24	$2M	$4M
Q4 24	$233K	$5M
Q1 25	$15K	$2M
Q2 25	$12M	$9M
Q3 25	$20M	$6M
Q4 25	$95M	$9M

Revenue Segments

Quarter	Reportable Segment	Product
Q2 25	$3M	—
Q3 25	—	$31M

War Chest

Quarter	Cash	Short-term Investments	Total
Q1 23	$65M	$0	$65M
Q2 23	$58M	$0	$58M
Q3 23	$49M	$0	$49M
Q4 23	$42M	$0	$42M
Q1 24	$31M	$0	$31M
Q2 24	$22M	$0	$22M
Q3 24	$14M	$0	$14M
Q4 24	$11M	$0	$11M
Q1 25	$6M	$0	$6M
Q2 25	$153M	$0	$153M
Q3 25	$133M	$0	$133M
Q4 25	$213M	$0	$213M

Shares Outstanding

Shares Outstanding

Quarter	Shares (Diluted)	QoQ Change
Q1 23	60M	+13.9%
Q2 23	64M	+6.5%
Q3 23	64M	+0.1%
Q4 23	64M	+0.1%
Q1 24	64M	+0.1%
Q2 24	64M	+0.0%
Q3 24	64M	+0.0%
Q4 24	64M	+0.0%
Q1 25	65M	+0.1%
Q2 25	77M	+19.6%
Q3 25	104M	+34.8%
Q4 25	104M	+0.2%

Revenue Per Employee

Revenue / Employee

Year	Revenue/Employee	Employees
FY 14	$442K	34
FY 15	$528K	38
FY 16	$440	42
FY 17	$0	40
FY 18	$0	50
FY 19	$0	57
FY 20	$188K	54
FY 21	$22K	52
FY 22	$2K	39
FY 23	$286	35
FY 24	$0	4
FY 25	$246K	44